News
SONN
2.030
-0.25%
-0.005
Weekly Report: what happened at SONN last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at SONN last week (0311-0315)?
Weekly Report · 03/18 12:21
RNLX, ASLN and SONN among pre-market losers
Seeking Alpha · 03/12 12:28
Weekly Report: what happened at SONN last week (0304-0308)?
Weekly Report · 03/11 12:16
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
TipRanks · 03/11 11:42
Weekly Report: what happened at SONN last week (0226-0301)?
Weekly Report · 03/04 12:21
Sonnet BioTherapeutics Announces A Publication Demonstrating Safety And Tolerability Of SON-1010 In Healthy Volunteers
Sonnet BioTherapeutics Holdings, Inc. Has published clinical data on SON-1010 in Frontiers in Immunology. The drug is a tumor-targeted, interleukin-12-linked, albumin-binding cytokine. The company is developing targeted immunotherapeutic drugs for cancer. In the B16F10 melanoma model, a single dose of the drug reduced tumor growth.
Benzinga · 02/29 21:25
Weekly Report: what happened at SONN last week (0219-0223)?
Weekly Report · 02/26 12:41
Weekly Report: what happened at SONN last week (0212-0216)?
Weekly Report · 02/19 12:43
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 02/15 17:45
Sonnet BioTherapeutics Price Target Cut to $30.00/Share From $75.00 by Chardan Capital
Dow Jones · 02/15 17:45
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
Benzinga · 02/15 17:35
Buy Recommendation for Sonnet BioTherapeutics: Clinical Progress and Strong Financial Position
TipRanks · 02/15 12:56
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 31 cents per share. The mean expectation of three analysts was for a loss of 90 cents. Revenue was $18.63 million; analysts expected revenue of $17.60 million.
Reuters · 02/14 17:14
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Cogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. Lineage Cell Therapeutics (AMEX:LCTX) stock rose 18.62% during the session. Alaunos Therapeutic stock increased by 17.39%. Losers Anitra stock declined by 67.8% and QuidelOrtho stock fell 39.35%.
Benzinga · 02/14 13:05
Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $0.31 per share. The company reported quarterly sales of $18.63 thousand. Sonnet Bio Therapeutics beat the analyst consensus estimate of losses by 65.56 percent.
Benzinga · 02/14 13:00
Sonnet BioTherapeutics GAAP EPS of -$0.31, revenue of $18.63M
Seeking Alpha · 02/14 12:50
Sonnet BioTherapeutics GAAP EPS of -$0.31
Seeking Alpha · 02/14 12:37
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares increased by 25.0% to $17.43 during Tuesday's after-market session. Sonnet BioTherapeutics stock moved upwards by 13.46% in Tuesday's session. Losers QuidelOrtho stock declined by 28.2% and NanoString Technologies stock decreased by 7.09%.
Benzinga · 02/13 21:31
Weekly Report: what happened at SONN last week (0205-0209)?
Weekly Report · 02/12 12:27
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.